We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

APH:NYSEAmphenol Corporation Analysis

Data as of 2026-03-09 - not real-time

$136.06

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Amphenol (APH) is trading at $136.06, which sits well above its DCF‑derived fair value of roughly $98 and carries a trailing P/E of 40.7 versus an industry average of 36.9, indicating a premium valuation. Revenue surged 49% YoY to $23.1 bn and margins remain solid (gross 37%, operating 27%, profit 18%), while ROE stands at an impressive 36.9%, underscoring strong profitability. The company’s cash position ($11.4 bn) comfortably exceeds its debt ($16.1 bn), and a modest 22% payout ratio supports the 0.76% dividend as sustainable. Recent strategic moves—including the acquisition of CommScope’s Connectivity and Cable Solutions business to bolster AI data‑center offerings—add a compelling growth catalyst.
Technical indicators are mixed: the 20‑day SMA ($143.48) sits above price, MACD is bearish, and RSI at 44 suggests neither overbought nor oversold conditions, while volatility is elevated (73% 30‑day) and beta is 1.29, pointing to heightened price swings. Given the overvaluation but strong fundamentals and dividend safety, the stock warrants a cautious stance in the short run, with upside potential as the acquisition integration proceeds.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish MACD histogram
  • Price near recent support level
  • Premium valuation relative to DCF

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Robust 49% revenue growth
  • Strategic acquisitions expanding AI data‑center exposure
  • Sustainable dividend with low payout ratio

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • High ROE and strong cash generation
  • Long‑term demand for high‑speed connectors across multiple industries
  • Continued growth through integration of recent acquisitions

Key Metrics & Analysis

Financial Health

Revenue Growth49.10%
Profit Margin18.49%
P/E Ratio40.7
ROE36.85%
ROA13.11%
Debt/Equity118.94
P/B Ratio12.4
Op. Cash Flow$5.4B
Free Cash Flow$3.3B
Industry P/E36.8

Technical Analysis

TrendNeutral
RSI44.3
Support$127.60
Resistance$154.05
MA 20$143.48
MA 50$143.93
MA 200$122.94
MACDBearish
VolumeIncreasing
Fear & Greed Index100

Valuation

Fair Value$97.66
Target Price$169.44
Upside/Downside24.54%
GradeOvervalued
TypeGrowth
Dividend Yield0.76%

Risk Assessment

Beta1.29
Volatility73.15%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.